Dual PPARα/γ ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines

Cell Cycle

Volumn 5, Issue 19, 2006, Pages 2237-2243

  Zang, Chuanbing ^a   Liu, Hongyu ^a   Waechter, Marlies ^a   Eucker, Jan ^a   Bertz, Janina ^a   Possinger, Kurt ^a   Koeffler, H Phillip ^b   Elstner, Elena ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; CML; Imatinib; PPAR ligand; Proliferation; TZD18

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; IMATINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (3 (3 (4 PHENOXY 2 PROPYLPHENOXY)PROPOXY)PHENYL) 2,4 THIAZOLIDINEDIONE; 5-(3-(3-(4-PHENOXY-2-PROPYLPHENOXY)PROPOXY)PHENYL)-2,4-THIAZOLIDINEDIONE; ANTINEOPLASTIC AGENT; DIPHENYL ETHER DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; WESTERN BLOTTING; DRUG EFFECT; DRUG POTENTIATION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PHENYL ETHERS; PIPERAZINES; PPAR ALPHA; PPAR GAMMA; PYRIMIDINES; THIAZOLIDINEDIONES;

EID: 33749634311     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.19.3259     Document Type: Article

References (33)

1. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 2001; 61:2343-55.
2. Ilaria Jr RL. Pathobiology of lymphoid and myeloid blast crisis and management issues. Education book for the 47th annual meeting of American Society of Hematology 2006;188-94.
3. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507-14.
4. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8:1224-34.
5. Elstner E, Mueller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95:8806-11.
6. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Possinger K, Koeffler HP. Novel therapeutic approach: Ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002; 74:155-65.
7. Zang C, Wachter M, Liu H, Posch MG, Fenner MH, Stadelmann C, von Deimling A, Possinger K, Black KL, Koeffler HP, Elstner E. Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol 2003; 65:107-18.
8. Eucker J, Bangeroth K, Zavrski I, Krebbel H, Zang C, Heider U, Jakob C, Elstner E, Possinger K, Sezer O. Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. Anticancer Drugs 2004; 15:955-60.
9. Zang C, Liu H, Posch MG, Waechter M, Facklam M, Fenner MH, Ruthardt M, Possinger K, Phillip KH, Elstner E. Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res 2004; 28:387-97.
10. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088-93.
11. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 2000; 15:416-21.
12. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393:790-3.
13. Meyer K, Jia Y, Cao WQ, Kashireddy P, Rao MS. Expression of peroxisome proliferator-activated receptor alpha, and PPARalpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA oxidase null mice. Int J Oncol 2002; 21:1175-80.
14. Canuto RA, Muzio G, Maggiora M, Trombetta A, Martinasso G, Autelli R, Costelli P, Bonelli G, Baccino FM. Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: Role of HMG-CoA reductase. J Lipid Res 2003; 44:56-64.
15. Muzio G, Maggiora M, Trombetta A, Martinasso G, Reffo P, Colombatto S, Canuto RA. Mechanisms involved in growth inhibition induced by clofibrate in hepatoma cells. Toxicology 2003; 187:149-59.
16. Jiao HL, Zhao BL. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol 2002; 185:172-9.
17. Strakova N, Ehrmann J, Bartos J, Malikova J, Dolezel J, Kolar Z. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 2005; 52:126-36.
18. Crowe DL, Chandraratna RA. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 2004; 6:R546-R555.
19. Scatena R, Nocca G, Sole PD, Rumi C, Puggioni P, Remiddi F, Bottoni P, Ficarra S, Giardina B. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 1999; 6:781-7.
20. Bronfman M, Ponce C, Rojas S, Roth A, Loyola G, Vollrath V, Chianale J. Enhanced differentiation of HL-60 leukemia cells to macrophages induced by ciprofibrate. Eur J Cell Biol 1998; 77:214-9.
21. Desai RC, Han W, Metzger EJ, Bergman JP, Gratale DF, MacNaul KL, Berger JP, Doebber TW, Leung K, Moller DE, Heck JV, Sahoo SP. 5-aryl thiazolidine-2,4-diones: Discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. Bioorg Med Chem Lett 2003; 13:2795-8.
22. Desai RC, Gratale DF, Han W, Koyama H, Metzger E, Lombardo VK, MacNaul KL, Doebber TW, Berger JP, Leung K, Franklin R, Moller DE, Heck JV, Sahoo SP. Aryloxazolidinediones: Identification of potent orally active PPAR dual alpha/gamma agonists. Bioorg Med Chem Lett 2003; 13:3541-4.
23. Guo Q, Sahoo SP, Wang PR, Milot DP, Ippolito MC, Wu MS, Baffic J, Biswas C, Hernandez M, Lam MH, Sharma N, Han W, Kelly LJ, MacNaul KL, Zhou G, Desai R, Heck JV, Doebber TW, Berger JP, Moller DE, Sparrow CP, Chao YS, Wright SD. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology 2004; 145:1640-8.
24. Liu DC, Zang CB, Liu HY, Possinger K, Fan SG, Elstner E. A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol Sin 2004; 25:1312-9.
25. Liu H, Zang C, Fenner MH, Liu D, Possinger K, Koeffler HP, Elstner E. Growth inhibition and apoptosis in human Philadelphia chromosome positive lymphoblastic leukemia cell lines by treatment with the dual PPAR{alpha}/{gamma} ligand TZD18. Blood 2006.
26. Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP. 20-epi-vitamin D3 analogues: A novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995; 55:2822-30.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
28. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 2006; 58:1-14.
29. Pizzimenti S, Laurora S, Briatore F, Ferretti C, Dianzani MU, Barrera G. Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. Free Radic Biol Med 2002; 32:233-45.
30. Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 2002; 277:6838-45.
31. Tauchi T, Ohyashiki K. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res 2004; 28(Suppl 1):S39-S45.
32. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin Jr AS. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998; 12:968-81.
33. Hamdane M, David-Cordonnier MH, D'Halluin JC. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene 1997; 15:2267-75.